AstraZeneca Reports Positive Results for Lung Cancer Combo Trial in China

Key Facts

1AstraZeneca announced that a late-stage Chinese trial showed significantly improved progression-free survival.

2The combination therapy uses Tagrisso and Orpathys as a first-line treatment for a specific type of lung cancer.

In a move reflecting the ongoing expansion of oncology treatments in major Asian markets, AstraZeneca has reported positive clinical trial outcomes in China. According to reports, a late-stage trial showed significantly improved progression-free survival for patients with a specific type of lung cancer. The combination therapy utilizes the drugs Tagrisso and Orpathys as a first-line treatment for advanced cases.

These results strengthen the company's position in the specialized pharmaceutical sector, as the study evaluated the efficacy of combining two existing cancer therapies. Per market data, the AZN.L stock closed at 11970 GBX (close August 28, 2026), having reached a day high of 12200 GBX during that session.

Traders should watch the current levels for AZN.L, which saw a day low of 11958 GBX as of the August 28, 2026 snapshot. In the absence of immediate upcoming sector-specific catalysts in the economic calendar, the focus remains on potential regulatory progress following these trial results in the Chinese market.